Thursday, September 24, 2026
EnglishEnglishРусскийEspañolFrançaisPortuguêsالعربية
The Global WireHorizon Global News

Credited outlet

Mashable News Staff

1 story written by The Global Wire newsroom from reporting first published by Mashable News Staff. Full credit for the original reporting belongs to them.

Visit Mashable News Staff →

Stories credited to Mashable News Staff

Novo Nordisk and Eli Lilly Face Lawsuits Over Alleged GLP-1 Vision Loss Risks
TechnologySource: Mashable News Staff

Novo Nordisk and Eli Lilly Face Lawsuits Over Alleged GLP-1 Vision Loss Risks

Product liability lawsuits claim semaglutide and tirzepatide treatments can cause permanent optic nerve damage, expanding legal scrutiny of popular weight-loss drugs.